AU5159798A - Branched peptide linkers - Google Patents
Branched peptide linkersInfo
- Publication number
- AU5159798A AU5159798A AU51597/98A AU5159798A AU5159798A AU 5159798 A AU5159798 A AU 5159798A AU 51597/98 A AU51597/98 A AU 51597/98A AU 5159798 A AU5159798 A AU 5159798A AU 5159798 A AU5159798 A AU 5159798A
- Authority
- AU
- Australia
- Prior art keywords
- peptide linkers
- branched peptide
- branched
- linkers
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3036796P | 1996-11-05 | 1996-11-05 | |
| US60030367 | 1996-11-05 | ||
| PCT/US1997/019851 WO1998019705A1 (en) | 1996-11-05 | 1997-10-31 | Branched peptide linkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5159798A true AU5159798A (en) | 1998-05-29 |
Family
ID=21853889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU51597/98A Abandoned AU5159798A (en) | 1996-11-05 | 1997-10-31 | Branched peptide linkers |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0941120A4 (en) |
| JP (1) | JP2001505194A (en) |
| AU (1) | AU5159798A (en) |
| CA (1) | CA2264610A1 (en) |
| WO (1) | WO1998019705A1 (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739028B2 (en) * | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
| US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
| KR20000052829A (en) | 1996-10-28 | 2000-08-25 | 조오지 디빈센조, 토브 아스 헬지, 에바 요한손 | Improvements in or relating to diagnostic/therapeutic agents |
| US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| AU1172599A (en) * | 1997-11-18 | 1999-06-07 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
| KR100581443B1 (en) * | 1998-05-22 | 2006-05-23 | 다이이찌 세이야꾸 가부시기가이샤 | Drug complex |
| CA2348931A1 (en) * | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Dds compound and method for measurement thereof |
| WO2000050059A1 (en) * | 1999-02-24 | 2000-08-31 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
| EP1176985A2 (en) * | 1999-04-28 | 2002-02-06 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| HK1049997B (en) | 1999-11-24 | 2007-02-23 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| DE10048417A1 (en) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Branched linker connections |
| IL157993A0 (en) | 2001-03-23 | 2004-03-28 | Napro Biotherapeutics Inc | Molecular conjugates for use in cancer treatment and methods for the preparation thereof |
| AU2002366303B2 (en) * | 2001-12-17 | 2007-09-20 | University College Cardiff Consultants Limited | Enzymatic cleavable reagents for specific delivery to disease sites |
| US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| BR0313197A (en) | 2002-08-02 | 2005-08-09 | Immunogen Inc | Cytotoxic agents containing potent taxanes and their therapeutic use |
| AU2003256038A1 (en) * | 2002-08-30 | 2004-03-19 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| AU2003282624A1 (en) * | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| WO2004081538A2 (en) | 2003-03-13 | 2004-09-23 | Irm, Llc | Compositions and methods of vinyl oxazolone polymerization |
| US20040228831A1 (en) * | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| CA2534708A1 (en) * | 2003-08-05 | 2005-02-17 | Wisconsin Alumni Research Foundation | Targeted carrier fusions for delivery of chemotherapeutic agents |
| ES2408704T3 (en) | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Crypto binding molecules |
| AU2007303205A1 (en) * | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| CA2860579A1 (en) | 2012-01-10 | 2013-07-18 | Biogen Idec Ma Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
| WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2015095223A2 (en) * | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| BR112016013861A2 (en) * | 2013-12-16 | 2017-10-10 | Genentech Inc | drug and antibody conjugates, compounds, treatment method and pharmaceutical composition |
| ES2885686T3 (en) | 2014-02-17 | 2021-12-15 | Seagen Inc | Hydrophilic Antibody-Drug Conjugates |
| US10533059B2 (en) * | 2014-03-12 | 2020-01-14 | Akamara Therapeutics, Inc. | Targeted drug delivery through affinity based linkers |
| KR101628872B1 (en) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | Compounds comprising self-immolative group |
| HRP20210809T8 (en) | 2014-10-29 | 2021-09-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for mt1-mmp |
| JP2018524295A (en) | 2015-06-15 | 2018-08-30 | ジェネンテック， インコーポレイテッド | Antibodies and immune complexes |
| JP7120765B2 (en) | 2015-11-25 | 2022-08-17 | レゴケム バイオサイエンシズ， インク． | CONJUGATES CONTAINING PEPTIDE GROUPS AND RELATED METHODS |
| SMT202400223T1 (en) | 2015-11-25 | 2024-07-09 | Ligachem Biosciences Inc | Conjugates comprising self-immolative groups and methods related thereto |
| KR102847350B1 (en) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | Antibody-drug conjugate comprising a branched linker and method for preparing the same |
| JP7664680B2 (en) | 2017-03-29 | 2025-04-18 | リガケム バイオサイエンシズ， インク． | Pyrrolobenzodiazepine dimer precursors and their ligand-linker conjugate compounds |
| WO2019025811A1 (en) | 2017-08-04 | 2019-02-07 | Bicycletx Limited | Bicyclic peptide ligands specific for cd137 |
| AU2019225845B2 (en) | 2018-02-20 | 2024-06-20 | Seagen Inc. | Hydrophobic Auristatin F compounds and conjugates thereof |
| MX2020008791A (en) | 2018-02-23 | 2021-01-08 | Bicycletx Ltd | Multimeric bicyclic peptide ligands. |
| SG11202010443WA (en) | 2018-05-09 | 2020-11-27 | Legochem Biosciences Inc | Compositions and methods related to anti-cd19 antibody drug conjugates |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3897734A4 (en) * | 2018-12-21 | 2022-12-07 | Seagen Inc. | ADCS WITH THIOL-MULTIPLEX LINKERS |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI862640B (en) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
| KR20210028544A (en) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use |
| WO2021178725A1 (en) | 2020-03-04 | 2021-09-10 | Verve Therapeutics, Inc. | Compositions and methods for targeted rna delivery |
| CA3189761A1 (en) | 2020-08-03 | 2022-02-10 | Gemma Mudd | Peptide-based linkers |
| CN116368226A (en) | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | Compositions and methods for capping RNA |
| CN116348479A (en) | 2020-09-30 | 2023-06-27 | 豪夫迈·罗氏有限公司 | Bacterial pilus protein complex FimGt-DsF stabilizes protein complexes for filamentous phage generation |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CA3222015A1 (en) * | 2021-06-01 | 2022-12-08 | Ajinomoto Co., Inc. | Conjugates of antibody and functional substance or salts thereof, and compounds used in production of the same or salts thereof |
| CN116333032B (en) * | 2021-12-22 | 2025-07-11 | 上海复旦张江生物医药股份有限公司 | Method for preparing high-purity small molecule peptide compounds by chromatography |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084560A (en) * | 1986-06-30 | 1992-01-28 | Oncogen | Immunoconjugates and methods for their use in tumor therapy |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5017693A (en) * | 1987-12-02 | 1991-05-21 | Neorx Corporation | Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound |
| US5563250A (en) * | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| IL106992A (en) * | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
| US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| IT1240643B (en) * | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| WO1992017505A1 (en) * | 1991-04-05 | 1992-10-15 | Board Of Regents Of The University Of Washington | Monoclonal antibodies to stem cell factor receptors |
| US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
-
1997
- 1997-10-31 EP EP97946428A patent/EP0941120A4/en not_active Withdrawn
- 1997-10-31 JP JP52160698A patent/JP2001505194A/en not_active Ceased
- 1997-10-31 CA CA002264610A patent/CA2264610A1/en not_active Abandoned
- 1997-10-31 WO PCT/US1997/019851 patent/WO1998019705A1/en not_active Ceased
- 1997-10-31 AU AU51597/98A patent/AU5159798A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998019705A1 (en) | 1998-05-14 |
| JP2001505194A (en) | 2001-04-17 |
| CA2264610A1 (en) | 1998-05-14 |
| EP0941120A1 (en) | 1999-09-15 |
| EP0941120A4 (en) | 2004-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU5159798A (en) | Branched peptide linkers | |
| AU3049397A (en) | Cyclosporin-containing pharmaceutical composition | |
| AU4922497A (en) | Interleukin-18-receptor proteins | |
| AU2972097A (en) | Peptide derivatives | |
| AU6721696A (en) | Cd44-like protein | |
| AU1803597A (en) | Peptide derivatives | |
| AU4427296A (en) | Novel peptide | |
| AU4394396A (en) | Modified peptides | |
| AU2131195A (en) | Prophenins - antibiotic peptides | |
| AU4967397A (en) | Water-soluble peptides | |
| AU5061698A (en) | Peptide derivatives | |
| AU2181197A (en) | Connecting part | |
| AU1999999A (en) | Contryphan peptides | |
| AU5764898A (en) | Multiple branch peptide constructions | |
| AUPM489194A0 (en) | Peptides | |
| AU5161296A (en) | Anti-haemorrhagic peptides | |
| AUPO324096A0 (en) | Linker peptide | |
| AU9109098A (en) | Hypusine peptides | |
| AU2233497A (en) | Peptide derivatives | |
| AUPO383096A0 (en) | Novel peptides | |
| AUPO061096A0 (en) | Novel peptides | |
| AUPO216596A0 (en) | Novel peptides | |
| AUPO330996A0 (en) | Novel peptides | |
| AUPO434796A0 (en) | Novel peptides | |
| AUPO268096A0 (en) | Cytotoxic peptides |